Dynamic Technology Lab Private Ltd Has $589,000 Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Dynamic Technology Lab Private Ltd raised its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 18.8% in the fourth quarter, Holdings Channel reports. The fund owned 27,429 shares of the company’s stock after acquiring an additional 4,340 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in Denali Therapeutics were worth $589,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of DNLI. Vanguard Group Inc. lifted its holdings in Denali Therapeutics by 3.5% during the 3rd quarter. Vanguard Group Inc. now owns 10,597,781 shares of the company’s stock worth $218,632,000 after buying an additional 354,798 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Denali Therapeutics by 3.6% in the third quarter. Wellington Management Group LLP now owns 7,288,960 shares of the company’s stock valued at $150,371,000 after acquiring an additional 250,784 shares during the last quarter. Federated Hermes Inc. increased its position in Denali Therapeutics by 27.1% in the third quarter. Federated Hermes Inc. now owns 1,351,900 shares of the company’s stock worth $27,890,000 after purchasing an additional 288,400 shares during the period. Norges Bank bought a new stake in Denali Therapeutics during the 4th quarter worth about $24,736,000. Finally, Dimensional Fund Advisors LP lifted its position in Denali Therapeutics by 15.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,119,628 shares of the company’s stock valued at $24,030,000 after purchasing an additional 146,394 shares during the period. 92.92% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DNLI has been the subject of a number of recent research reports. The Goldman Sachs Group dropped their price target on shares of Denali Therapeutics from $73.00 to $50.00 and set a “buy” rating for the company in a research note on Thursday, February 29th. Stifel Nicolaus cut their price target on Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating on the stock in a research note on Wednesday, May 8th. Wedbush decreased their price objective on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Wednesday, May 8th. HC Wainwright reissued a “buy” rating and issued a $95.00 target price on shares of Denali Therapeutics in a research note on Wednesday, May 8th. Finally, UBS Group decreased their target price on Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, April 9th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $40.22.

Denali Therapeutics Trading Down 4.0 %

Denali Therapeutics stock opened at $19.26 on Friday. Denali Therapeutics Inc. has a twelve month low of $14.56 and a twelve month high of $33.31. The company has a 50 day moving average of $18.60 and a 200-day moving average of $18.87.

Denali Therapeutics (NASDAQ:DNLI) last released its earnings results on Tuesday, May 7th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. Denali Therapeutics had a negative return on equity of 11.46% and a negative net margin of 36.51%. During the same quarter in the previous year, the firm posted ($0.80) earnings per share. As a group, analysts anticipate that Denali Therapeutics Inc. will post -2.77 EPS for the current fiscal year.

Insider Activity at Denali Therapeutics

In related news, Director Steve E. Krognes sold 92,500 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the completion of the transaction, the director now owns 47,341 shares in the company, valued at $970,490.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Steve E. Krognes sold 92,500 shares of the company’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $20.50, for a total transaction of $1,896,250.00. Following the sale, the director now owns 47,341 shares in the company, valued at $970,490.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 1,666 shares of the firm’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $18.29, for a total value of $30,471.14. Following the completion of the transaction, the director now owns 118,043 shares of the company’s stock, valued at $2,159,006.47. The disclosure for this sale can be found here. 7.90% of the stock is owned by insiders.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.